70810-24-1 Usage
General Description
1,7-Dichloroisoquinoline is a chemical compound with the molecular formula C9H5Cl2N. It is a pale yellow crystalline solid that is primarily used in organic synthesis and as a building block for pharmaceuticals and agrochemicals. 1,7-Dichloroisoquinoline has been shown to exhibit antifungal and antibacterial properties, making it a useful ingredient in the development of new drugs. It is also utilized in the production of dyes, herbicides, and insecticides. The compound is highly stable and can be stored and transported safely under recommended conditions. Due to its diverse range of applications, 1,7-Dichloroisoquinoline is considered an important intermediate in the chemical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 70810-24-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,0,8,1 and 0 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 70810-24:
(7*7)+(6*0)+(5*8)+(4*1)+(3*0)+(2*2)+(1*4)=101
101 % 10 = 1
So 70810-24-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H5Cl2N/c10-7-2-1-6-3-4-12-9(11)8(6)5-7/h1-5H
70810-24-1Relevant articles and documents
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 00950; 00953, (2021/01/22)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
Hepatitis C Virus Inhibitors
-
Page/Page column 139, (2008/12/05)
Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.